Drug Profile
Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences
Alternative Names: PMN 267 - ALS therapeutic; PMN 300; PMN 320; PMN 330; PMN 340; PMN 350; TDP 43 targeting therapeuticsLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Amorfix Life Sciences
- Developer ProMIS Neurosciences
- Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Superoxide dismutase inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- No development reported Alzheimer's disease; Dementia; Down syndrome; Lewy body disease; Multiple system atrophy; Parkinson's disease
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Multiple system atrophy in Canada (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in Canada (Parenteral)
- 28 Oct 2021 No recent reports of development identified for research development in Lewy body disease in Canada (Parenteral)